The Future of the EMBLEM™ S-ICD: Results from the UNTOUCHED Trial скачать в хорошем качестве

The Future of the EMBLEM™ S-ICD: Results from the UNTOUCHED Trial

Watch Dr. Michael Gold discuss the results from the UNTOUCHED study. The results of this study demonstrated an inappropriate shock free rate of 95.9% at 18 months. With a 98.4% final shock efficacy in terminating ventricular arrhythmias, these findings highlight the efficacy of the EMBLEM S-ICD. Safety info: https://bit.ly/3kxVIzq ©2025 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are the property of their respective owners. Prior to use, please see the complete “Directions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions at www.IFU-BSCI.com. Rx only. CRM-900305-AA | CRM-2114615-AA Chapters: 0:00 - Introduction 0:17 - Overview of EMBLEM S-ICD 0:55 - Challenges of First-Generation S-ICD Devices 1:29 - UNTOUCHED Study Objectives and Background 2:01 - UNTOUCHED Study Design and Inclusion Criteria 2:25 - Primary and Secondary Endpoints 3:10 - Patient Demographics and Baseline Data 4:00 - Procedural Details and Use of 3rd Gen Devices 4:41 - Primary Endpoint Results 5:06 - Predictors of Inappropriate Shocks 5:47 - Comparison of Device Generations and Techniques 6:14 - Impact of Two-Incision vs. Three-Incision Techniques 7:00 - Historical Comparison with Previous S-ICD Studies 8:18 - All-Cause Shock Rate and Predictors 8:54 - Efficacy of S-ICD Therapy 9:34 - Complication Rates and Study Safety Outcomes 11:00 - Overall Survival and Arrhythmic Deaths 12:00 - Study Conclusions and Key Takeaways 12:45 - Importance of Prospective Registry Trials 14:00 - Real-World Applications of S-ICD Studies 15:00 - Generation 2 vs. Generation 3 Devices and Smart Pass Filter 16:24 - Impacts on Device Implantation Techniques 18:20 - Future Analyses and Long-Term Studies